Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Board declares interim dividend of Rs 2 per equity share
This work has been published in the journal ‘ACS applied materials and interface’
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Subscribe To Our Newsletter & Stay Updated
